Overview

The Efficacy and Safety of Sildenafil Citrate Used in Combination With Intravenous Epoprostenol in PAH

Status:
Completed
Trial end date:
2006-01-01
Target enrollment:
Participant gender:
Summary
Determination of the effects of sildenafil citrate and epoprostenol when used in combination in patients with pulmonary arterial hypertension
Phase:
Phase 3
Details
Lead Sponsor:
Pfizer
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Collaborator:
Pfizer
Treatments:
Citric Acid
Sildenafil Citrate